Leonoor Wijnans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Leonoor Wijnans has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Jeanne Dieleman
Erasmus Medical Center, Rotterdam, The Netherlands
2 shared publicationsMiriam Sturkenboom
Erasmus Medical Center, Rotterdam, The Netherlands
2 shared publications- Anneke Steens
National Institute for Public Health and the Environment
1 shared publication Bettie Voordouw
Medicines Evaluation Board, Utrecht, The Netherlands
1 shared publication- Jan Bonhoeffer
University of Basel Children's Hospital, Basel, Switzerland
1 shared publication - Jeanne P. Dieleman
Department of Medical Informatics and Epidemiology, Erasmus University Medical Centre, Rotterdam, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 30 April 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4) , e63156
Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands
Background The aim of the present study was to estimate the effectiveness of the MF59™-adjuvanted influenza A(H1N1)pdm09 vaccine against medically attended influenza-like illness and RT-PCR confirmed influenza in the at-risk population and persons over 60 in the Netherlands. Methods We conducted a retrospective cohort study in a Dutch based GP medical record database between 30 November 2009 and 1 March 2010 to estimate the vaccine effectiveness against influenza-like illness. Within the cohort we nested a test negative case-control study to estimate the effectiveness against laboratory confirmed influenza. Results The crude effectiveness in preventing diagnosed or possible influenza-like illness was 17.3% (95%CI: −8.5%–36.9%). Of the measured covariates, age, the severity of disease and health seeking behaviour through devised proxies confounded the association between vaccination and influenza-like illness. The adjusted vaccine effectiveness was 20.8% (95%CI: −5.4%, 40.5%) and varied significantly by age, being highest in adults up to 50 years (59%, 95%CI: 23%, 78%), and non-detectable in adults over 50 years. The number of cases in the nested case control study was too limited to validly estimate the VE against confirmed influenza. Conclusions With our study we demonstrated that the approach of combining a cohort study in a primary health care database with field sampling is a feasible and useful option to monitor VE of influenza vaccines in the future.
- 30 April 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4) , e63156
Open AccessEffectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands
Background The aim of the present study was to estimate the effectiveness of the MF59™-adjuvanted influenza A(H1N1)pdm09 vaccine against medically attended influenza-like illness and RT-PCR confirmed influenza in the at-risk population and persons over 60 in the Netherlands. Methods We conducted a retrospective cohort study in a Dutch based GP medical record database between 30 November 2009 and 1 March 2010 to estimate the vaccine effectiveness against influenza-like illness. Within the cohort we nested a test negative case-control study to estimate the effectiveness against laboratory confirmed influenza. Results The crude effectiveness in preventing diagnosed or possible influenza-like illness was 17.3% (95%CI: −8.5%–36.9%). Of the measured covariates, age, the severity of disease and health seeking behaviour through devised proxies confounded the association between vaccination and influenza-like illness. The adjusted vaccine effectiveness was 20.8% (95%CI: −5.4%, 40.5%) and varied significantly by age, being highest in adults up to 50 years (59%, 95%CI: 23%, 78%), and non-detectable in adults over 50 years. The number of cases in the nested case control study was too limited to validly estimate the VE against confirmed influenza. Conclusions With our study we demonstrated that the approach of combining a cohort study in a primary health care database with field sampling is a feasible and useful option to monitor VE of influenza vaccines in the future.
- Open Access
- 18 July 2011
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 11 (1) , 196
Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study
During the 2009 influenza A/H1N1 pandemic, adjuvanted influenza vaccines were used for the first time on a large scale. Results on the effectiveness of the vaccines in preventing 2009 influenza A/H1N1-related hospitalisation are scanty and varying.
- 18 July 2011
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 11 (1) , 196
Open AccessEffectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study
During the 2009 influenza A/H1N1 pandemic, adjuvanted influenza vaccines were used for the first time on a large scale. Results on the effectiveness of the vaccines in preventing 2009 influenza A/H1N1-related hospitalisation are scanty and varying.